Easily Available Blood Test Neutrophil-To-Lymphocyte Ratio Predicts Progression in High-Risk Non-Muscle Invasive Bladder Cancer
| Autor: | Călin Bogdan Chibelean, Daniel Porav-Hodade, Orsolya Martha, Octavian Sabin Tătaru, Mihai Dorin Vartolomei, Anca Sin, Daniel Balan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Bladder cancer medicine.diagnostic_test business.industry fungi 030232 urology & nephrology prognostic factors medicine.disease 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine Blood test bladder cancer microinvasive Medicine Neutrophil to lymphocyte ratio Non muscle invasive business neutrophil-to-lymphocytes ratio |
| Zdroj: | Romanian Journal of Laboratory Medicine, Vol 25, Iss 2, Pp 181-189 (2017) |
| ISSN: | 2284-5623 |
| Popis: | Introduction: The inflammatory response surrounding the tumour has a major importance in the oncologic outcome of bladder cancers. One marker proved to be useful and accessible is NLR (neutrophil-to-lymphocyte ratio). The objective of the study was the analysis of NLR as a prognostic factor for recurrence and progression in pT1a and pT1b bladder cancers. Material and Methods: Retrospective study, with 44 T1a/T1b bladder cancer patients. Each patient underwent transurethral resection. NLR was considered altered if higher than 3, average follow-up period was of 18 months. Results: The mean age of the patients included was 73 years (IQR 64 - 77). Most of the patients had NLR3 and other clinic and pathologic factors. Progression-free survival (PFS) Kaplan-Meier analysis showed a lower PFS in the NLR>3 group, with a p=0.001 value. A total of 64.3% of patients had shown progression in the NLR>3 group and 20% in the NLR Conclusion: High Neutrophil-to-Lymphocyte ratio retained a statistically significant value, as an independent prognostic factor for bad prognosis of T1 bladder tumors. NLR represents a biomarker that could support a clinical decision making in case of high-risk on-muscle invasive bladder cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|